Brugada syndrome
Authors:
M. Bébarová
Authors place of work:
Fyziologický ústav Lékařské fakulty MU Brno, vedoucí ústavu prof. MUDr. Nataša Honzíková, CSc.
Published in the journal:
Vnitř Lék 2011; 57(6): 551-560
Category:
Reviews
Summary
Brugada syndrome (BrS) is, along with the long QT syndrome, one of the most frequently diagnosed inherited arrhythmogenic syndromes. It is a primary electric heart disease manifested by ST segment elevations in the right precordial leads. BrS is responsible for more than 4% of all sudden deaths and at least 20% of sudden deaths in patients with structurally normal hearts. In 1998, the first mutations in the gene coding the structure of the cardiac sodium channel were identified in patients with BrS. Nowadays, several hundreds of mutations in at least 8 genes have been already associated with BrS. Functional consequences of many of these mutations on the molecular level have been revealed and, in some of them, even the consequences for the overall cardiac electrophysiology were suggested thank to the mathematical modelling. However, despite intense study of many scientific teams and formulation of several hypotheses, arrhythmogenic mechanisms in BrS have not been fully elucidated yet. This review provides a contemporary view of clinical symptoms, pathophysiology, diagnostics and therapy in BrS.
Key words:
Brugada syndrome – arrhythmia – arrhythmogenesis – mutation
Zdroje
1. Brugada P, Brugada J. Right bundle branch block, persistent ST segment elevation and sudden cardiac death: a distinct clinical and electrocardiographic syndrome. A multicenter report. J Am Coll Cardiol 1992; 20: 1391–1396.
2. Antzelevitch C, Brugada P, Borggrefe M et al. Brugada syndrome: report of the second consensus conference: endorsed by the Heart Rhythm Society and the European Heart Rhythm Association. Circulation 2005; 111: 659–670.
3. Matsuo K, Akahoshi M, Nakashima E et al. The prevalence, incidence and prognostic value of the Brugada-type electrocardiogram: a population-based study of four decades. J Am Coll Cardiol 2001; 38: 765–770.
4. Gervacio-Domingo G, Isidro J, Tirona J et al. The Brugada type 1 electrocardiographic pattern is common among Filipinos. J Clin Epidemiol 2008; 61: 1067–1072.
5. Pecini R, Cedergreen P, Theilade S et al. The prevalence and relevance of the Brugada-type electrocardiogram in the Danish general population: data from the Copenhagen City Heart Study. Europace 2010; 12: 982–986.
6. Gallagher MM, Forleo GB, Behr ER et al. Prevalence and significance of Brugada-type ECG in 12,012 apparently healthy European subjects. Int J Cardiol 2008; 130: 44–48.
7. Blangy H, Sadoul N, Coutelour JM et al. Prevalence of Brugada syndrome among 35,309 inhabitants of Lorraine screened at a preventive medicine centre. Arch Mal Coeur Vaiss 2005; 98: 175–180.
8. Letsas KP, Gavrielatos G, Efremidis M et al. Prevalence of Brugada sign in a Greek tertiary hospital population. Europace 2007; 9: 1077–1080.
9. Wilde AA, Postema PG, Di Diego JM et al. The pathophysiological mechanism underlying Brugada syndrome Depolarization versus repolarization. J Mol Cell Cardiol 2010; 49: 543–553.
10. Mádle A, Kratochvíl Z, Polívková A. The Brugada syndrome. Vnitř Lék 2002; 48: 255–258.
11. Veiser T, Laurent G, Wolf JE. Brugada syndrome. Čas Lék Česk 2005; 144: 219–223.
12. Mádle A. Electrocardiography in the diagnosis of genetic heart diseases – the Brugada syndrome. Vnitř Lék 2002; 48 (Suppl 1): 144–146.
13. Antzelevitch C. Brugada syndrome. Pacing Clin Electrophysiol 2006; 29: 1130–1159.
14. Ariyarajah V, Smith H, Hodge S et al. Spontaneous alternans in Brugada ST-segment morphology within minutes. J Electrocardiol 2008; 41: 302–305.
15. Tatsumi H, Takagi M, Nakagawa E et al. Risk stratification in patients with Brugada syndrome: analysis of daily fluctuations in 12-lead electrocardiogram (ECG) and signal-averaged electrocardiogram (SAECG). J Cardiovasc Electrophysiol 2006; 17: 705–711.
16. Francis J, Antzelevitch C. Atrial fibrillation and Brugada syndrome. J Am Coll Cardiol 2008; 51: 1149–1153.
17. Morita H, Kusano-Fukushima K, Nagase S et al. Atrial fibrillation and atrial vulnerability in patients with Brugada syndrome. J Am Coll Cardiol 2002; 40: 1437–1444.
18. Kusano KF, Taniyama M, Nakamura K et al. Atrial fibrillation in patients with Brugada syndrome relationships of gene mutation, electrophysiology, and clinical backgrounds. J Am Coll Cardiol 2008; 51: 1169–1175.
19. Bordachar P, Reuter S, Garrigue S et al. Incidence, clinical implications and prognosis of atrial arrhythmias in Brugada syndrome. Eur Heart J 2004; 25: 879–884.
20. Morita H, Fukushima-Kusano K, Nagase S et al. Site-specific arrhythmogenesis in patients with Brugada syndrome. J Cardiovasc Electrophysiol 2003; 14: 373–379.
21. Allocca G, Proclemer A, Nucifora G et al. Monomorphic ventricular tachycardia in “Brugada syndrome”: clinical case and literature review. J Cardiovasc Med (Hagerstown) 2008; 9: 842–846.
22. Matsuo K, Kurita T, Inagaki M et al. The circadian pattern of the development of ventricular fibrillation in patients with Brugada syndrome. Eur Heart J 1999; 20: 465–470.
23. Shimizu W, Matsuo K, Takagi M et al. Body surface distribution and response to drugs of ST segment elevation in Brugada syndrome: clinical implication of eighty-seven-lead body surface potential mapping and its application to twelve-lead electrocardiograms. J Cardiovasc Electrophysiol 2000; 11: 396–404.
24. Takigawa M, Noda T, Shimizu W et al. Seasonal and circadian distributions of ventricular fibrillation in patients with Brugada syndrome. Heart Rhythm 2008; 5: 1523–1527.
25. Remme CA, Wever EF, Wilde AA et al. Diagnosis and long-term follow-up of the Brugada syndrome in patients with idiopathic ventricular fibrillation. Eur Heart J 2001; 22: 400–409.
26. Benito B, Brugada J, Brugada R et al. Brugada syndrome. Rev Esp Cardiol 2009; 62: 1297–1315.
27. Meregalli PG, Wilde AA, Tan HL. Pathophysiological mechanisms of Brugada syndrome: depolarization disorder, repolarization disorder, or more? Cardiovasc Res 2005; 67: 367–378.
28. Yan GX, Antzelevitch C. Cellular basis for the Brugada syndrome and other mechanisms of arrhythmogenesis associated with ST-segment elevation. Circulation 1999; 100: 1660–1666.
29. Antzelevitch C. The Brugada syndrome: ionic basis and arrhythmia mechanisms. J Cardiovasc Electrophysiol 2001; 12: 268–272.
30. Cordeiro JM, Mazza M, Goodrow R et al. Functionally distinct sodium channels in ventricular epicardial and endocardial cells contribute to a greater sensitivity of the epicardium to electrical depression. Am J Physiol Heart Circ Physiol 2008; 295: H154–H162.
31. Wettwer E, Amos GJ, Posival H et al. Transient outward current in human ventricular myocytes of subepicardial and subendocardial origin. Circ Res 1994; 75: 473–482.
32. Näbauer M, Beuckelmann DJ, Uberfuhr P et al. Regional differences in current density and rate-dependent properties of the transient outward current in subepicardial and subendocardial myocytes of human left ventricle. Circulation 1996; 93: 168–177.
33. Di Diego JM, Cordeiro JM, Goodrow RJ et al. Ionic and cellular basis for the predominance of the Brugada syndrome phenotype in males. Circulation 2002; 106: 2004–2011.
34. Fish JM, Antzelevitch C. Cellular and ionic basis for the sex-related difference in the manifestation of the Brugada syndrome and progressive conduction disease phenotypes. J Electrocardiol 2003; 36 (Suppl): 173–179.
35. Matsuo K, Akahoshi M, Seto S et al. Disappearance of the Brugada-type electrocardiogram after surgical castration: a role for testosterone and an explanation for the male preponderance. Pacing Clin Electrophysiol 2003; 26: 1551–1553.
36. Shimizu W, Matsuo K, Kokubo Y et al. Sex hormone and gender difference – role of testosterone on male predominance in Brugada syndrome. J Cardiovasc Electrophysiol 2007; 18: 415–421.
37. Bai CX, Kurokawa J, Tamagawa M et al. Nontranscriptional regulation of cardiac repolarization currents by testosterone. Circulation 2005; 112: 1701–1710.
38. Fülöp L, Bányász T, Szabó G et al. Effects of sex hormones on ECG parameters and expression of cardiac ion channels in dogs. Acta Physiol (Oxf) 2006; 188: 163–171.
39. Ridley JM, Shuba YM, James AF et al. Modulation by testosterone of an endogenous hERG potassium channel current. J Physiol Pharmacol 2008; 59: 395–407.
40. Nagase S, Kusano KF, Morita H et al. Epicardial electrogram of the right ventricular outflow tract in patients with the Brugada syndrome: using the epicardial lead. J Am Coll Cardiol 2002; 39: 1992–1995.
41. Tukkie R, Sogaard P, Vleugels J et al. Delay in right ventricular activation contributes to Brugada syndrome. Circulation 2004; 109: 1272–1277.
42. Papavassiliu T, Wolpert C, Flüchter S et al. Magnetic resonance imaging findings in patients with Brugada syndrome. J Cardiovasc Electrophysiol 2004; 15: 1133–1138.
43. Papavassiliu T, Veltmann C, Doesch C et al. Spontaneous type 1 electrocardiographic pattern is associated with cardiovascular magnetic resonance imaging changes in Brugada syndrome. Heart Rhythm 2010; 7: 1790–1796.
44. Coronel R, Casini S, Koopmann TT et al. Right ventricular fibrosis and conduction delay in a patient with clinical signs of Brugada syndrome: a combined electrophysiological, genetic, histopathologic, and computational study. Circulation 2005; 112: 2769–2777.
45. Chen Q, Kirsch GE, Zhang D et al. Genetic basis and molecular mechanism for idiopathic ventricular fibrillation. Nature 1998; 392: 293–296.
46. Antzelevitch C, Nof E. Brugada syndrome: recent advances and controversies. Curr Cardiol Rep 2008; 10: 376–383.
47. Hedley PL, Jørgensen P, Schlamowitz S et al. The genetic basis of Brugada syndrome: a mutation update. Hum Mutat 2009; 30: 1256–1266.
48. London B, Michalec M, Mehdi H et al. Mutation in glycerol-3-phosphate dehydrogenase 1 like gene (GPD1-L) decreases cardiac Na+ current and causes inherited arrhythmias. Circulation 2007; 116: 2260–2268.
49. Watanabe H, Koopmann TT, Le Scouarnec S et al. Sodium channel beta1 subunit mutations associated with Brugada syndrome and cardiac conduction disease in humans. J Clin Invest 2008; 118: 2260–2268.
50. Delpón E, Cordeiro JM, Núñez L et al. Functional effects of KCNE3 mutation and its role in the development of Brugada syndrome. Circ Arrhythm Electrophysiol 2008; 1: 209–218.
51. Hu D, Barajas-Martinez H, Burashnikov E et al. A mutation in the beta 3 subunit of the cardiac sodium channel associated with Brugada ECG phenotype. Circ Cardiovasc Genet 2009; 2: 270–278.
52. Burashnikov E, Pfeiffer R, Barajas-Martinez H et al. Mutations in the Cardiac L-Type Calcium Channel Associated with Inherited J Wave Syndromes and Sudden Cardiac Death. Heart Rhythm 2010; 7: 1872–1882.
53. Cordeiro JM, Barajas-Martinez H, Hong K et al. Compound heterozygous mutations P336L and I1660V in the human cardiac sodium channel associated with the Brugada syndrome. Circulation 2006; 114: 2026–2033.
54. Lizotte E, Junttila MJ, Dube MP et al. Genetic modulation of brugada syndrome by a common polymorphism. J Cardiovasc Electrophysiol 2009; 20: 1137–1141.
55. Verkerk AO, Wilders R, Schulze-Bahr E et al. Role of sequence variations in the human ether-a-go-go-related gene (HERG, KCNH2) in the Brugada syndrome. Cardiovasc Res 2005; 68: 441–453.
56. Tan HL. Sodium channel variants in heart disease: expanding horizons. J Cardiovasc Electrophysiol 2006; 17 (Suppl 1): S151–S157.
57. Van Norstrand DW, Valdivia CR, Tester DJ et al. Molecular and functional characterization of novel glycerol-3-phosphate dehydrogenase 1 like gene (GPD1-L) mutations in sudden infant death syndrome. Circulation 2007; 116: 2253–2259.
58. Keller DI, Rougier JS, Kucera JP et al. Brugada syndrome and fever: genetic and molecular characterization of patients carrying SCN5A mutations. Cardiovasc Res 2005; 67: 510–519.
59. Abriel H. Cardiac sodium channel Na(v)1.5 and interacting proteins: Physiology and pathophysiology. J Mol Cell Cardiol 2010; 48: 2–11.
60. Huo J, Zhang Y, Huang N et al. The G604S-hERG mutation alters the biophysical properties and exerts a dominant-negative effect on expression of hERG channels in HEK293 cells. Pflugers Arch 2008; 456: 917–928.
61. Labro AJ, Boulet IR, Timmermans JP et al. The rate-dependent biophysical properties of the LQT1 H258R mutant are counteracted by a dominant negative effect on channel trafficking. J Mol Cell Cardiol 2010; 48: 1096–1104.
62. Clancy CE, Rudy Y. Na(+) channel mutation that causes both Brugada and long-QT syndrome phenotypes: a simulation study of mechanism. Circulation 2002; 105: 1208–1213.
63. Miyoshi S, Mitamura H, Fukuda Y et al. Link between SCN5A mutation and the Brugada syndrome ECG phenotype: simulation study. Circ J 2005; 69: 567–575.
64. Antzelevitch C, Pollevick GD, Cordeiro JM et al. Loss-of-function mutations in the cardiac calcium channel underlie a new clinical entity characterized by ST-segment elevation, short QT intervals, and sudden cardiac death. Circulation 2007; 115: 442–449.
65. Cordeiro JM, Marieb M, Pfeiffer R et al. Accelerated inactivation of the L-type calcium current due to a mutation in CACNB2b underlies Brugada syndrome. J Mol Cell Cardiol 2009; 46: 695–703.
66. Fish JM, Antzelevitch C. Role of sodium and calcium channel block in unmasking the Brugada syndrome. Heart Rhythm 2004; 1: 210–217.
67. Yap YG, Behr ER, Camm AJ. Drug-induced Brugada syndrome. Europace 2009; 11: 989–994.
68. Bébarová M, O‘Hara T, Geelen JL et al. Subepicardial phase 0 block and discontinuous transmural conduction underlie right precordial ST-segment elevation by a SCN5A loss-of-function mutation. Am J Physiol Heart Circ Physiol 2008; 295: H48–H58.
69. Petitprez S, Jespersen T, Pruvot E et al. Analyses of a novel SCN5A mutation (C1850S): conduction vs. repolarization disorder hypotheses in the Brugada syndrome. Cardiovasc Res 2008; 78: 494–504.
70. Amin AS, Klemens CA, Verkerk AO et al. Fever-triggered ventricular arrhythmias in Brugada syndrome and type 2 long-QT syndrome. Neth Heart J 2010; 18: 165–169.
71. Postema PG, Wolpert C, Amin AS et al. Drugs and Brugada syndrome patients: review of the literature, recommendations, and an up-to-date website (www.brugadadrugs.org). Heart Rhythm 2009; 6: 1335–1341.
72. Brugada R, Brugada J, Antzelevitch C et al. Sodium channel blockers identify risk for sudden death in patients with ST-segment elevation and right bundle branch block but structurally normal hearts. Circulation 2000; 101: 510–515.
73. Veltmann C, Wolpert C, Sacher F et al. Response to intravenous ajmaline: a retrospective analysis of 677 ajmaline challenges. Europace 2009; 11: 1345–1352.
74. Brugada J, Brugada R, Brugada P. Pharmacological and device approach to therapy of inherited cardiac diseases associated with cardiac arrhythmias and sudden death. J Electrocardiol 2000; 33 (Suppl): 41–47.
75. Nademanee K, Veerakul G, Mower M et al. Defibrillator Versus beta-Blockers for Unexplained Death in Thailand (DEBUT): a randomized clinical trial. Circulation 2003; 107: 2221–2226.
76. Sacher F, Probst V, Iesaka Y et al. Outcome after implantation of a cardioverter-defibrillator in patients with Brugada syndrome: a multicenter study. Circulation 2006; 114: 2317–2324.
77. Rosso R, Glick A, Glikson M et al. Israeli Working Group on Cardiac Pacing and Electrophysiology. Outcome after implantation of cardioverter defibrillator in patients with Brugada syndrome: a multicenter Israeli study (ISRABRU). Isr Med Assoc J 2008; 10: 435–439.
78. Sarkozy A, Boussy T, Kourgiannides G et al. Long-term follow-up of primary prophylactic implantable cardioverter-defibrillator therapy in Brugada syndrome. Eur Heart J 2007; 28: 334–344.
79. Krivan L, Kozák M, Sepsi M et al. Specifické komplikace terapie implantabilními kardiovertery defibrilátory. Čas Lék Čes 2004; 143: 521–525.
80. Lin G, Nishimura RA, Gersh BJ et al. Device complications and inappropriate implantable cardioverter defibrillator shocks in patients with hypertrophic cardiomyopathy. Heart 2009; 95: 709–714.
81. Glikson M, Lipchenca I, Viskin S et al. Long-term outcome of patients who received implantable cardioverter defibrillators for stable ventricular tachycardia. J Cardiovasc Electrophysiol 2004; 15: 658–664.
82. Bailey SM, Wilkoff BL. Complications of pacemakers and defibrillators in the elderly. Am J Geriatr Cardiol 2006; 15: 102–107.
83. Alings M, Dekker L, Sadée A et al. Quinidine induced electrocardiographic normalization in two patients with Brugada syndrome. Pacing Clin Electrophysiol 2001; 24: 1420–1422.
84. Belhassen B, Glick A, Viskin S. Efficacy of quinidine in high-risk patients with Brugada syndrome. Circulation 2004; 110: 1731–1737.
85. Imaizumi Y, Giles WR. Quinidine-induced inhibition of transient outward current in cardiac muscle. Am J Physiol 1987; 253: H704–H708.
86. Wang Z, Fermini B, Nattel S. Effects of flecainide, quinidine, and 4-aminopyridine on transient outward and ultrarapid delayed rectifier currents in human atrial myocytes. J Pharmacol Exp Ther 1995; 272: 184–196.
87. Dukes ID, Morad M. Tedisamil inactivates transient outward K+ current in rat ventricular myocytes. Am J Physiol 1989; 257: H1746–H1749.
88. Ohgo T, Okamura H, Noda T et al. Acute and chronic management in patients with Brugada syndrome associated with electrical storm of ventricular fibrillation. Heart Rhythm 2007; 4: 695–700.
89. Tsuchiya T, Ashikaga K, Honda T et al. Prevention of ventricular fibrillation by cilostazol, an oral phosphodiesterase inhibitor, in a patient with Brugada syndrome. J Cardiovasc Electrophysiol 2002; 13: 698–701.
90. Abud A, Bagattin D, Goyeneche R et al. Failure of cilostazol in the prevention of ventricular fibrillation in a patient with Brugada syndrome. J Cardiovasc Electrophysiol 2006; 17: 210–212.
91. Fish JM, Welchons DR, Kim YS et al. Dimethyl lithospermate B, an extract of Danshen, suppresses arrhythmogenesis associated with the Brugada syndrome. Circulation 2006; 113: 1393–1400.
92. Yoon JY, Ahn SH, Oh H et al. A novel Na+ channel agonist, dimethyl lithospermate B, slows Na+ current inactivation and increases action potential duration in isolated rat ventricular myocytes. Br J Pharmacol 2004; 143: 765–773.
93. Haïssaguerre M, Extramiana F, Hocini M et al. Mapping and ablation of ventricular fibrillation associated with long-QT and Brugada syndromes. Circulation 2003; 108: 925–928.
94. Mlčochová H, Kautzner J, Peichl P et al. Katetrizační ablace fibrilace komor: realita nebo fikce? Kardiol Rev 2006; 8 (Suppl): 43–46.
95. Nademanee K, Veerakul G, Chandanamattha P et al. Prevention of ventricular fibrillation episodes in brugada syndrome by catheter ablation over the anterior right ventricular outflow tract epicardium. Circulation 2011; 123: 1270–1279.
96. Shah AJ, Hocini M, Lamaison D et al. Regional Substrate Ablation Abolishes Brugada Syndrome. J Cardiovasc Electrophysiol 2011; doi: 10.1111/j.1540–8167.2011.02054.x.
Štítky
Diabetology Endocrinology Internal medicineČlánok vyšiel v časopise
Internal Medicine
2011 Číslo 6
Najčítanejšie v tomto čísle
- Brugada syndrome
- Primary hepatic carcinoid
- Long-term outcome of catheter ablation therapy of supraventricular tachyarrhythmias
- Seniors and cardiovascular medications